Kissei Pharmaceutical Co., Ltd. (TYO:4547)

Market Cap	161.25B -0.7%
Revenue (ttm)	97.41B +10.3%
Net Income	13.78B +15.2%
EPS	331.53 +20.9%
Shares Out	41.45M
PE Ratio	11.73
Forward PE	15.11
Dividend	130.00 (3.34%)
Ex-Dividend Date	Mar 30, 2026

Volume	118,300
Open	3,900.00
Previous Close	3,875.00
Day's Range	3,875.00 - 3,945.00
52-Week Range	3,500.00 - 5,040.00
Beta	-0.15
Analysts	Buy
Price Target	5,216.67 (+34.11%)
Earnings Date	May 11, 2026

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of rena...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 1,778
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4547

Financial Performance

In fiscal year 2026, Kissei Pharmaceutical's revenue was 97.41 billion, an increase of 10.28% compared to the previous year's 88.33 billion. Earnings were 13.78 billion, an increase of 15.20%.